Company: Atara Biotherapeutics Inc.
Job title: CSO
VIRTUAL Off-the-Shelf Allogeneic EBV T Cells: Ushering in the Next Wave of Innovation 3:00 pm
Discuss the journey that led to the historic EU approval of the first-ever allogeneic T-cell therapy globally Highlight the qualities that make allogeneic Epstein-Barr virus (EBV) T cells a highly versatile platform for targeting EBV-driven disease Explore how this platform can be modified with a chimeric antigen receptor (CAR) to target a wide range of…Read more
day: Bootcamp Day